Prior to joining Actin Biomed, Dr. Weiser was the Director of Research at Paramount BioCapital, Inc., a pharmaceutical development and healthcare investment firm. She holds an undergraduate degree from the University of California, Los Angeles and an M.D. His role as a Leader in the Clinical Development field is a result of the multiple responsibilities and duties he has undertaken in the Pharmaceutical industry: Andes Biotechnologies GitLab Inc. announced the acquisition of Opstrace, Inc., an open-source observability distribution, on December 14, 2021. Here's a list of some of the top trending technologies and APIs used by Acerta Pharma. Prior to Calistoga, Dr. Ulrich was Senior Scientific Director with Merck Research Laboratories/Rosetta Inpharmatics, Director of Regulatory Toxicology, Safety Pharmacology, Genetic Toxicology, Cellular and Molecular Toxicology, Microscopy and Microanalysis at Abbott Laboratories, and a Senior Scientist with The Upjohn Company and Pharmacia & Upjohn Inc. Dr. Ulrich holds several patents and has authored more than 125 publications. Prior to joining Kartos, Dr. Slatter was VP for DMPK/Clinical Pharmacology at Acerta Pharma (a member of the AstraZeneca Group, 2014-18); Scientific Director (PKDM) and Medical Sciences Director (Clinical Pharmacology/Early Development) at Amgen (2006-14); Scientific Director (Preclinical Molecular Profiling) at Rosetta Inpharmatics/Merck (2003-06); Scientist II-IV (Drug Metabolism Research) and Associate Director (Life Cycle Management) at Pharmacia/Upjohn (1990-2003). Previously, Dr. Dukes was Vice President of Scientific and Technology Licensing at GlaxoSmithKline, and he held various positions at Glaxo Wellcome, including Head of Exploratory Development for Metabolic and Urogenital Diseases and Head of Ion Channel Drug Discovery Group. Get the full list, To view Acerta Pharmas complete patent history, request access, Youre viewing 1 of 18 executive team members. Bitfury conducts blockchain research and makes research reports, whitepapers, and educational materials available on its website. Flavia is the retired Chief Executive Officer for Acerta Pharma, where she led the organization to the approval of Calquence for Mantle Cell Lymphoma; she also served as the Global Franchise Head, Hematology at AstraZeneca, with responsibility for the hematology portfolio in the Oncology Business Unit. Valuation- $ 1 Billion The startup unicorn began operations in 2013 intending to deliver revolutionary targeted medicines for cancer patients by combining cutting-edge science, unique covalent technology , and an experienced, motivated workforce. He is a member of the American Society for Clinical Investigation and is co-founder and an Executive Committee Member of the International Working Group for MF Treatment and Research. Flow has headquarters in New York, London, Milan, Paris, Cluj-Napoca, Singapore, and Hong Kong, and was started in Amsterdam, Netherlands. According to a new analysis from NRC and Dealroom, the Netherlands startup ecosystem is thriving, and the country is home to 12 unicorns. Learn more. It even claimed that it would issue free bunq bank accounts to Ukrainian refugees. Mr. Rothbaum graduated Phi Beta Kappa from Binghamton University in 1990 with a dual major in political science and psychology and received his MA in international economics from The George Washington University. Founded in Netherlands in 2012 to develop treatments for cancers and autoimmune diseases, Acerta Pharma ran in stealth mode, driving investors and over 20 clinical trials for monotherapy and in combination with other targeted molecules. The products overseen by Dr. Hamdy ranges across all clinical development phases (15 Phase I, 17 Phase II, 8 Phase III, and 3 Phase IV trials) and he has a successful track record of delivering numerous INDs and NDAs. As a member of the Executive Committee at BMS, she was deeply involved with the strategy and activities that transformed BMS into a highly successful specialty biopharmaceutical company. The Netherlands is pedalling to the top of the European startup leadership tables, thanks to its open culture and open attitude toward startups, a concentration on invention and entrepreneurship, and an all-around sense of satisfaction throughout society. Valuation- $ 2 Billion At our recently expanded site at Oss in the Netherlands, we have core capabilities in target identification, target validation, lead generation and compound optimization. Prior to his role at Oxford, Mr. Sandler held various finance roles of increasing responsibility at Hyperion Therapeutics, Complete Genomics, Ipsen, Nektar Therapeutics, and Genentech. Todd holds a BA in Physiology and Cell Biology from UC Santa Barbara. Vincerx Pharma's executive team, experts in innovative medicines Claim your profile to get in front of buyers, investors, and analysts. He has extensive experience in clinical operations and clinical development of both small and large-molecule therapies across a range of oncology indications. It has grown to a strong team of 700 individuals from over 55 nationalities since 2011 and is delighted to be a Work Anywhere company. It provides a payment API that allows merchants to accept payments both online and through mobile apps. Before Acerta Pharma, Mr. Salva served as Senior Director of Corporate Development at Pharmacyclics, where he participated in the strategic turnaround of the company that reprioritized focus. Iceland, Norway, Canada, and the Republic of Georgia all have their data centres. Acerta Pharma B.v. (a Member Of The Astrazeneca Group) specialises in pharmaceuticals. Its financial services are available to inhabitants of 30 European nations as of 2019. Bunq is the bank of The Free. Board of Directors - Iovance Biotherapeutics Acerta Pharma B.v. (a Member Of The Astrazeneca Group) is a Pharmaceuticals company and has headquarters in North Brabant, Netherlands. In February 2016, AstraZeneca acquired a majority share of Acerta Pharma via a USD $4 billion investment and is a committed partner to the development of these innovative drugs. He has also served as President and Chief Executive Officer, as well as a member of the Board of Directors of Essentialis Therapeutics, a clinical stage biotechnology company focused on the development of breakthrough medicines for the treatment of rare metabolic diseases. Email: information.center@astrazeneca.com. The company specializes in the field of covalent binding technology to create novel, highly selective therapies for cancer, thereby enabling medical professionals to improve outcomes and enhance the lives of patients. Prior to this, he was an Equity Research Analyst covering Global Pharma and Biotech companies at various financial institutions. Find contact's direct phone number, email address, work history, and more. Bunq is often referred to be a disruptor or challenger bank. User deposits exceeded 1.2 billion euros in 2021. You can read more about your. It uses organised deployment pipelines to push the CI-validated code into the application. Dr. Countouriotis is the President and Chief Executive Officer and a member of the Board of Directors of Turning Point Therapeutics. It emphasises professional and personal development and urges its employees to be the best at whatever they do by providing the appropriate training. Only 18 months after creating the startup, the company disclosed raising $70 million in a Series C fundraising round in June 2014. Bitfury is developing solutions for the future using the most important millennium technology. The Bitfury Group is a global leader in full-service blockchain technology. From 2000 to 2007, Dr. Dukes was Vice President of Scientific and Technology Licensing at GlaxoSmithKline, and prior to that, from 1990 to 1999, he held various positions at Glaxo Wellcome, including Head of Exploratory Development for Metabolic and Urogenital Diseases and Head of Ion Channel Drug Discovery Group. Wayne Rothbaum is president of Quogue Capital, a single-family office private equity fund focused on investing and supporting small to midcap life sciences companies. Several large companies, including eBay, Cisco, and Microsoft, employ Elastic to power mission-critical systems. As a comprehensive DevOps Platform, GitLabs application provides the capability to jointly plan, build, protect, and deploy software. The Netherlands has catapulted itself to the top of the European startup leaderboards, and it is identified as one of the worlds most interconnected economies as well as the fourth-best European country for startup movement, thanks to a holy trinity of a globally competitive talent pool, an abundance of incubator programmes, and a booming tech sector. The technology platform acts as a payment gateway and a payment service provider, at the same time providing risk management and local acquiring. Previously, Dr. Dixon held executive management positions at West Pharmaceuticals, Osteotech and Centocor, as well as various positions at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. Vice President Europe & Site Head Acerta Oss. Jurriaan Dekkers CEO. Another advantage for Dutch companies is the ready availability of a skilled and bilingual workforce, thanks to the Dutch educational system. Phase I/II data showing a favourable safety profile and strong efficacy in relapsed/refractory chronic lymphocytic leukaemia patients was presented at the American Society of Hematology Annual Meeting & Exposition in December 2015, with simultaneous publication in the New England Journal of Medicine. Ahmed Hamdy Co-Founder, & Board Member. He joined the Iovance Board of Directors in July 2011, and served as the interim Chief Executive Officer of Iovance from January 2013 until July 2013. He completed his internship and residency in internal medicine at SUNY at Buffalo, NY, and his fellowship in hematology/oncology at MD Anderson Cancer Center. Hotmart Company has now allowed millions of creators to sell their work in almost every country on the planet. Acertas lead drug, Calquence (acalabrutinib) was approved by the FDA for mantle cell lymphoma in 2017 and chronic lymphocytic leukemia in 2020. Dr. Weiser previously served as the Chairman of the Board of Directors of Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company that was acquired by H. Lundbeck A/S in 2014. Her previous roles include Senior Director, Pharmacology & Toxicology at Acerta Pharma (2014-2018); Senior Program Scientist, Experimental Medicine at Seattle Genetics (2011-13); Principal Scientist, Mechanistic and Applied Pharmacology at ZymoGenetics (2004-09); and Senior Scientist, BioPrint at Cerep (2001-04). He was a Fellow at The Rockefeller University from 1993 to 1995. The unicorn has enough mining projects to be considered a well-established player in the global bitcoin market. Elastic was listed on the New York Stock Exchange on October 5, 2018. Mollie spun off some of its business operations, resulting in the formation of the company. in Pharmacology from the University of Bath. Dmitriy Zaporozhets of Ukraine and Sytse Sijbrandij of the Netherlands collaborated on the open-source software project. 2. CBI websites generally use certain cookies to enable better interactions with our sites and services. Parque Tecnolgico Zaartu Bitfury bought the Hong Kong-based IT startup Allied Control in 2015. During that time, he managed projects focusing on the characterization of activated signaling networks in tumor cells and utilizing this knowledge to advance kinase inhibitors from the preclinical stage to the clinic. Acerta Pharma BV: ClinicalTrials.gov Identifier: NCT02475681 Other Study ID Numbers: ACE-CL-007 : First Posted: June 19, 2015 Key Record Dates: Results First Posted: January 10, 2023: Last Update Posted: March 29, 2023 Last Verified: March 2023 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: ACERTA PHARMA BV. We encourage you to read the privacy policy of every website you visit. Working together Acerta and AstraZeneca are focused on Innovative Clinical Strategies to enable us to combine our extensive oncology portfolio of cancer therapies. Most recently he served as Chief Scientific Officer and a member of the Board of Directors at Acerta Pharma BV until the majority acquisition by AstraZeneca in 2016. Acerta Pharma Founders Ahmed Hamdy, Co-Founder & VP R&D Allard Kaptein, Co-Founder Acerta Pharma Competitors ASLAN Pharmaceuticals 2010, Singapore, $100M Adicet Bio 2014, Menlo Park, $156M Ariad Pharmaceuticals 1991, Cambridge, $46M Allterum 2018, Houston, $65.8M & 84 others View complete profile Update InformationRemove Profile Erin is currently a Director in Amgens Business Development group where she leads oncology search and evaluation. Clients send messages through the website or API, which are then converted to speech. Dr. Dixon also established and served as the executive sponsor for the BMS Womens Affinity Network, focused on gender diversity and inclusion priorities. Acalabrutinib is a highly selective, irreversible, second generation BTK inhibitor, with approximately 1,000 patients treated to date in clinical studies across the entire development programme. Data centres are owned by this corporation in Iceland and the Republic of Georgia. Previously, Dr. Dixon served on the board of directors of Incyte Corporation, bluebird bio, Inc., Dentsply International, Furiex Pharmaceuticals, Orexigen Therapeutics, Sesen Bio, Inc. (formerly Eleven Biotherapeutics, Inc.), Ardea Biosciences, Inc. and Voyager Therapeutics, Inc. Dr. Dixon earned a B.Sc., an M.Sc. Top 10 Most Valuable Unicorns in Netherlands 2022 It was motivated to research AI, according to Valery Vavilov, the businesss CEO and co-founder, since the volume of data the company had accumulated had outstripped its ability to evaluate it efficiently. Dr. Hamdy previously served as the Chief Medical Officer for Pharmacyclics (2009-11). Having been a Nurse Practitioner (1994-2004) in SCT/Heme-malignancies at University of Colorado and US Oncology, Beth transitioned to Industry by joining Allos Therapeutics (2008-11) first in development, then moving to Medical Affairs for the launch of FOLOTYN.